论文部分内容阅读
目的:对不同手术方法治疗直肠癌肝转移的临床疗效进行研究,证实外科治疗的临床价值;方法:以我院2007年6月～2010年6月治疗的96例结直肠癌肝转移患者为研究对象,将其随机分为2组,每组48例。一组研究对象行直肠癌根治术后使用TPVCE介入或FOLFOX方案化疗进行治疗,为对照组;一组研究对象行直肠癌根治术的同时行Ⅰ期行肝切除术后使用TPVCE介入或FOLFOX方案化疗进行治疗,为观察组。对2组研究对象术后生存率、1年生存率及3年生存率进行比较,并进行统计学分析;结果:观察组术后生存率为95.8%,较对照组83.3%的术后生存率有显著优势,且具有统计学差异性(P<0.05);在术后1年和3年患者生存率的比较中,观察组均具有显著优势,且具有统计学差异性(P<0.05);结论:同时行直肠癌根治术和Ⅰ期行肝切除术联合化疗在结直肠癌肝转移的治疗中,较单纯行直肠癌根治术联合化疗的患者生存时间具有显著优势,适于临床推广。
OBJECTIVE: To study the clinical efficacy of different surgical methods for the treatment of liver metastases from rectal cancer, and to confirm the clinical value of surgical treatment.Methods: A total of 96 patients with liver metastases from colorectal cancer treated in our hospital from June 2007 to June 2010 Subjects were randomly divided into two groups, 48 cases in each group. One group of patients undergoing radical resection of rectal cancer with TPVCE intervention or FOLFOX regimen chemotherapy for the control group; a group of subjects underwent radical resection of colorectal cancer with a first phase hepatectomy using TPVCE intervention or FOLFOX regimen chemotherapy Treatment, for the observation group. The survival rate, 1-year survival rate and 3-year survival rate of two groups of subjects were compared and statistically analyzed. Results: The postoperative survival rate was 95.8% in the observation group, 83.3% in the control group (P <0.05). Compared with the survival rate of patients after 1 year and 3 years after operation, the observation group had significant advantages (P <0.05), and the difference was statistically significant (P <0.05). Conclusions: In the treatment of liver metastasis of colorectal cancer, concurrent radical resection of rectal cancer and primary hepatectomy combined with chemotherapy have a significant advantage over the radical rectal cancer combined with chemotherapy in the treatment of liver metastasis, which is suitable for clinical promotion.